Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

Frank Vinluan / medcitynews - Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Ass…

AI Summary: Eli Lilly’s triple‑agonist produced average weight loss exceeding 28% in a pivotal study, positioning the drug as a leader among late‑stage obesity candidates. The results close the gap with surgical outcomes and promise major clinical and commercial impact—assuming regulators are satisfied and long‑term safety and durability data hold up.


GLP-1 drugs closing gap with bariatric surgery

Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds

7 wks / medicalxpress

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

7 wks / nature / Chloe Stanley

GLP-1s are closing the gap with bariatric surgery. Here’s what the research shows.

7 wks / beckershospitalreview / Ella Jeffries


GLP-1 mechanisms and potential cancer benefits

GLP-1s and cancer outcomes: What new research shows

7 wks / beckershospitalreview / Elizabeth Gregerson

Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest

7 wks / medicalxpress

Researchers identify avenue for enhanced GLP-1-induced weight loss

7 wks / medicalxpress


Lilly’s retatrutide trial: 28% weight loss and implications

Inside Makary’s ouster; Another win for Lilly’s triple-G; and more

7 wks / endpoints / Max Gelman

Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

7 wks / medcitynews / Frank Vinluan

Lilly’s triple agonist still leads among late-stage obesity assets

7 wks / endpoints / Elizabeth Cairns

Experimental Drug Yields Dramatic Weight Loss

7 wks / nytimes / Gina Kolata and Rebecca Robbins


All Other Stories

Telehealth is Making GLP-1s More Accessible – But Access Alone isn’t Enough

5 wks / medcitynews / Ro Huntriss

ASCO 2026: updates on weight loss drugs and cancer

6 wks / cancerresearchuk / Tim Gunn

CVS obesity drug deal puts Lilly on equal footing with Novo

6 wks / healthcaredive / Kristin Jensen

Tirzepatide superior to intensified conventional care for early type 2 diabetes

6 wks / medicalxpress

Low-insulinemic, planetary health diets optimize weight management during menopause

6 wks / medicalxpress

EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug

7 wks / medicalxpress




Related Stories

Apitegromab preserves muscle while patients lose weight on GLP‑1s / 4 wks

Kailera plans IPO for obesity drug aiming to challenge Zepbound / 3 months

Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 3 months

Lilly fights classification ruling as stockpile and compounding lawsuits swirl / 4 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 7 months

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 3 months

FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 6 wks

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Hearing Loss, CDC, Product Recall and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.